Notwithstanding, the potential of multiple ex-US C
Post# of 148185
(Total Views: 739)
Posted On: 10/27/2020 6:05:45 PM
Quote:
Notwithstanding, the potential of multiple ex-US Combo HIV approvals, with the possibility of Mono Label Expansions, will be a nice adjunct to a COVID approval in Q1-2021.
Read More: https://investorshangout.com/post/view?id=594...z6c6ytFLZk
Agreed. If HIV combo/mono in several other countries would create a very nice floor for this stock. As well as a bridge to CD12 completion.
Doesnt help us save lives in COVID sooner, but it may in fact allow us to begin ramping up production sooner, which in turn could save more lives.
(3)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼